Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$42.42 - $80.28 $4.33 Million - $8.19 Million
102,005 Added 4259.08%
104,400 $7.68 Million
Q3 2023

Nov 14, 2023

SELL
$39.12 - $49.85 $78,435 - $99,949
-2,005 Reduced 45.57%
2,395 $110,000
Q2 2023

Aug 14, 2023

BUY
$23.58 - $44.68 $103,751 - $196,592
4,400 New
4,400 $185,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.6B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.